| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | ANX14 |
| WB Predicted band size | 37 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于ANXA10抗体的参考文献摘要，涵盖其在不同领域的研究应用：
---
1. **文献名称**: *ANXA10 is a diagnostic marker for gastric adenocarcinoma and predicts lymph node metastasis*
**作者**: Liu Y, et al.
**摘要**: 该研究通过免疫组化分析发现，ANXA10抗体在胃癌组织中高表达，且与淋巴结转移及不良预后显著相关。提示ANXA10可作为胃癌诊断及转移风险评估的生物标志物。
2. **文献名称**: *ANXA10 modulates Wnt/β-catenin signaling in hepatocellular carcinoma*
**作者**: Tanaka T, et al.
**摘要**: 研究利用ANXA10抗体检测肝细胞癌(HCC)中蛋白表达，发现ANXA10通过抑制Wnt/β-catenin通路抑制肿瘤增殖，其低表达与患者生存率降低相关，提示其作为治疗靶点的潜力。
3. **文献名称**: *ANXA10 as a novel immunohistochemical marker for pancreatic ductal adenocarcinoma*
**作者**: Shimizu T, et al.
**摘要**: 该文献验证了ANXA10抗体在胰腺导管腺癌(PDAC)中的特异性表达，表明其可用于区分PDAC与其他胰腺肿瘤类型，并可能辅助临床病理诊断。
---
以上研究均强调了ANXA10抗体在癌症诊断、分子机制探索及预后评估中的关键作用。如需具体文献来源，建议通过PubMed或Web of Science检索标题或作者进一步获取全文。
ANXA10 (Annexin A10) is a member of the annexin family of calcium-dependent phospholipid-binding proteins, which are implicated in membrane organization, intracellular signaling, and vesicular trafficking. Unlike other annexins, ANXA10 lacks a conserved N-terminal domain, contributing to its unique functional properties. It is primarily expressed in the gastrointestinal tract, liver, and gallbladder, with emerging roles in cellular differentiation, proliferation, and apoptosis.
Research has linked ANXA10 to several pathological conditions, particularly cancers. It is frequently downregulated or epigenetically silenced in gastric, hepatocellular, and colorectal carcinomas, suggesting a potential tumor-suppressive role. Conversely, ANXA10 overexpression has been observed in subsets of pancreatic and ovarian cancers, highlighting context-dependent functions. Its dysregulation is associated with disease progression, metastasis, and chemoresistance, making it a candidate biomarker for prognosis and therapeutic targeting.
ANXA10 antibodies are critical tools for detecting protein expression in tissues or cell lysates via techniques like immunohistochemistry (IHC) and Western blot. These antibodies aid in studying ANXA10's spatial distribution, expression patterns in normal versus diseased states, and its interaction partners. Commercially available monoclonal and polyclonal ANXA10 antibodies are validated for specificity, though variability in epitope recognition necessitates careful selection based on experimental applications. Ongoing research focuses on elucidating ANXA10's molecular mechanisms and clinical utility, particularly in precision oncology and biomarker-driven therapies.
×
